<div id="readability-page-1"><div><h2>Regulatory shift puts Capricor Therapeutics (CAPR) timelines under closer scrutiny</h2> <p>The FDA’s move to tighten its expedited approval pathway directly affects Capricor Therapeutics (CAPR). This places more attention on how its Duchenne muscular dystrophy program and other rare disease candidates progress through upcoming clinical and regulatory checkpoints.</p> <p>See our latest analysis for Capricor Therapeutics.</p> <p>Capricor Therapeutics’ share price has moved to US$27.90 after a recent 1 day share price return of 8.06%, while its 1 year total shareholder return of 117.80% and very large 3 year total shareholder return suggest momentum has been strong over a longer horizon, even with periods of softer recent performance as investors reassess risk around tighter FDA timelines.</p> <p>If regulatory changes around rare disease drugs have your attention, it might be a good moment to look at other potential opportunities through our 32 healthcare AI stocks.</p> <p>With Capricor posting a 1 year total shareholder return of 117.80%, very large 3 year gains and trading at US$27.90 versus a stated price target of US$50.80, you have to ask: is there still upside here, or is the market already baking in future growth?</p> <h2>Most Popular Narrative: 45.1% Undervalued</h2> <p>Capricor Therapeutics' most followed narrative anchors on a fair value of US$50.80, which sits well above the recent close at US$27.90 and puts the focus squarely on what needs to go right in its late stage programs to close that gap.</p> <blockquote> <p><em>The continued rise in the global prevalence of rare and genetic diseases is directly fueling unmet medical needs in areas like Duchenne Muscular Dystrophy (DMD), placing Capricor's Deramiocel in a strong position for regulatory support and future market demand, which could drive substantial revenue growth upon successful approval.</em></p> </blockquote> <p><em>With growing adoption of personalized and precision medicine, Capricor's advanced exosome platform is now in the clinic with StealthX, broadening potential future applications (beyond vaccines) and strategic partnerships, enabling pipeline diversification and supporting future earnings growth and revenue stability.</em></p> <p>Read the complete narrative.</p> <p>Want to understand why this narrative sees rare disease demand, exosome optionality and future margins lining up behind that fair value? The projections connect steep revenue expansion, a sharp swing into profitability and a premium future earnings multiple into one story. Curious which assumptions matter most if you are weighing that US$50.80 against today’s US$27.90?</p> <p><strong>Result: Fair Value of US$50.80 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this hinges on Deramiocel delivering against evolving FDA expectations and on Capricor managing rising R&amp;D spend and cash burn without heavier-than-expected dilution.</p> <p>Find out about the key risks to this Capricor Therapeutics narrative.</p> <h2>Next Steps</h2> <p>If this focus on fair value and risk has you thinking more critically about Capricor, it could be worth checking the underlying data yourself and moving quickly to form your own view. You can start by weighing the optimism priced into the rewards our analysis has identified through 3 key rewards.</p> <h2>Ready to find your next opportunity?</h2> <p>If Capricor has sharpened your thinking, do not stop here. The wider market is full of ideas that might fit your goals just as well.</p> <ul> <li>Spot potential bargains by checking companies our screener tags as 49 high quality undervalued stocks, so you are not relying on headlines alone.</li> <li>Prioritise resilience by reviewing 63 resilient stocks with low risk scores, helping you focus on businesses with risk profiles that may better match your comfort level.</li> <li>Hunt for fresher stories with our screener containing 24 high quality undiscovered gems, so you see names that might not yet be on everyone else’s radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

SBIO

CAPR

IBBQ

ARKG

<p>Capricor Therapeutics (CAPR) faces increased scrutiny as the FDA tightens its expedited approval pathway, impacting its Duchenne muscular dystrophy program. The company's share price recently rose to $27.90, with a one-year total shareholder return of 117.80%. Analysts suggest a fair value of $50.80, indicating potential upside. The narrative emphasizes the growing demand for rare disease treatments and Capricor's innovative exosome platform, which could drive future revenue growth. However, success hinges on meeting FDA expectations and managing R&D costs effectively.</p>

Simplywall

ALPS Medical Breakthrough

VanEck Biotech ETF

SPDR S&P Biotech

Capricor Therap

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

A Look At Capricor Therapeutics (CAPR) Valuation As FDA Tightens Expedited Approval Pathway